Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-010 in advanced solid tumors
NCT03713905Phase 1Completed
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Jul 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zimberelimab in gastric cancer (GC), esophageal cancer and solid tumor (advanced stage), sponsored by Guangzhou Gloria Biosciences Co., Ltd. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Jul 2017; status: completed.
02
Drugs
zimberelimab
03
Conditions
gastric cancer (GC)esophageal cancersolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03713905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713905.